Status and phase
Conditions
Treatments
About
To evaluate the efficacy and safety of neoadjuvant therapy of camrelizumab combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma
Full description
This study is a single-arm, open-label, exploratory clinical study, the main purpose of which is to evaluate the efficacy and safety of neoadjuvant treatment of camrelizumab combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma.
The patient will receive three cycles of treatment of camrelizumab(200 mg, IV., d1, q3w), paclitaxel(175 mg/m2,continuous IV., d1, 24h q3w), cisplatin(75 mg/m2, iv., d1,q3w).Patients who are assessed as being able to undergo surgical resection receive elective resection surgery,and the maintenance treatment of postoperative patients implements individualized treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Blood routine:
Liver and kidney function:
Normal coagulation function, no active bleeding and thrombotic disease
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
39 participants in 1 patient group
Loading...
Central trial contact
Peng Tang, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal